Figure 5.
Enhancement of topotecan anti-tumor activity in vivo against established experimental liver metastasis by mAb 8B6 specific for O-acetyl-GD2. (A) Mice (n = 10/group) were inoculated with 2.5 × 105 NXS2 cells by i.v. injections. mAb 8B6 treatment was started on day 3 after tumor cell inoculation twice a week for 3 consecutive weeks (cumulative dose = 150 µg). Topotecan treatment was started at day 10 post-tumor inoculation. Topotecan was given by i.p. injections at 0.36 mg/kg five times weekly for 1 week. Mice were euthanized 28 days post-tumor inoculation. (B) Anti-tumor efficacy was evaluated by determining the liver weight on the fresh specimen. The y-axis starts at 0.8 g corresponding to the average of normal liver weight. (C) Mean weight for each treatment group, as indicated. Mean weight of mice at day 0 was defined as 100% weight. Weight in each group remained stable for the period of treatment. Data are presented as the mean ± SEM. * p < 0.05.